Trial Profile
A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SIERRA
- Sponsors AstraZeneca
- 17 Nov 2023 Planned End Date changed from 13 Apr 2026 to 30 Dec 2025.
- 19 Oct 2023 Planned primary completion date changed from 10 Apr 2026 to 30 Jun 2025.
- 10 Jul 2023 Status changed from not yet recruiting to recruiting.